114 related articles for article (PubMed ID: 22924678)
21. Adherence of adolescents to multiple sclerosis disease-modifying therapy.
Thannhauser JE; Mah JK; Metz LM
Pediatr Neurol; 2009 Aug; 41(2):119-23. PubMed ID: 19589460
[TBL] [Abstract][Full Text] [Related]
22. Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy.
Curkendall SM; Wang C; Johnson BH; Cao Z; Preblick R; Torres AM; Knappertz V; Gondek K
Clin Ther; 2011 Jul; 33(7):914-25. PubMed ID: 21684600
[TBL] [Abstract][Full Text] [Related]
23. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis.
Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
Eur Neurol; 2008; 59(3-4):131-5. PubMed ID: 18057899
[TBL] [Abstract][Full Text] [Related]
24. [The effect of tobacco smoking on clinical effectiveness of immunomodulatory treatment in multiple sclerosis patients].
Jernas Ł; Piorunek T; Tokarz E; Wygladalska-Jernas H; Kozubski W; Michalak S
Przegl Lek; 2012; 69(10):750-2. PubMed ID: 23421025
[TBL] [Abstract][Full Text] [Related]
25. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.
Halpern R; Agarwal S; Borton L; Oneacre K; Lopez-Bresnahan MV
Adv Ther; 2011 Sep; 28(9):761-75. PubMed ID: 21870169
[TBL] [Abstract][Full Text] [Related]
26. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate.
Yildiz M; Tettenborn B; Putzki N
Eur Neurol; 2011; 65(4):231-2. PubMed ID: 21454981
[No Abstract] [Full Text] [Related]
27. Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.
Webb UH
J Neurosci Nurs; 2008 Dec; 40(6):356-61. PubMed ID: 19170303
[TBL] [Abstract][Full Text] [Related]
28. Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis.
Patten SB; Williams JV; Metz LM
Mult Scler; 2008 Apr; 14(3):406-11. PubMed ID: 17986504
[TBL] [Abstract][Full Text] [Related]
29. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
[TBL] [Abstract][Full Text] [Related]
30. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
31. Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients.
Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
Eur Neurol; 2009; 61(3):177-82. PubMed ID: 19129705
[TBL] [Abstract][Full Text] [Related]
32. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
Minden S; Hoaglin D; Jureidini S; Hadden L; Frankel D; Komatsuzaki Y; Outley J
Mult Scler; 2008 Jun; 14(5):640-55. PubMed ID: 18566028
[TBL] [Abstract][Full Text] [Related]
33. Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project.
Arroyo E; Grau C; Ramo-Tello C; Parra J; Sánchez-Soliño O;
Eur Neurol; 2011; 65(2):59-67. PubMed ID: 21212677
[TBL] [Abstract][Full Text] [Related]
34. Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.
Qizilbash N; Mendez I; Sanchez-de la Rosa R
Clin Ther; 2012 Jan; 34(1):159-176.e5. PubMed ID: 22284996
[TBL] [Abstract][Full Text] [Related]
35. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
36. Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Meca-Lallana JE; Balseiro JJ; Lacruz F; Guijarro C; Sanchez O; Cano A; Costa-Frossard L; Hernández-Clares R; Sanchez-de la Rosa R;
J Neurol Sci; 2012 Apr; 315(1-2):123-8. PubMed ID: 22133480
[TBL] [Abstract][Full Text] [Related]
37. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
McKay KA; Tremlett H; Patten SB; Fisk JD; Evans C; Fiest K; Campbell T; Marrie RA;
Mult Scler; 2017 Apr; 23(4):588-596. PubMed ID: 27357507
[TBL] [Abstract][Full Text] [Related]
38. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.
Praksova P; Stourac P; Bednarik J; Vlckova E; Mikulkova Z; Michalek J
J Neurol Sci; 2012 Aug; 319(1-2):18-23. PubMed ID: 22676847
[TBL] [Abstract][Full Text] [Related]
39. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis.
Nair KV; Corboy J; Kahler K; Allen RR; Ghushcyan V; McQueen RB; Bainbridge J; Dastani H; Mody-Patel N
Expert Rev Neurother; 2011 Jun; 11(6):787-98. PubMed ID: 21651327
[TBL] [Abstract][Full Text] [Related]
40. The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate.
Oleen-Burkey MA; Dor A; Castelli-Haley J; Lage MJ
J Med Econ; 2011; 14(6):739-47. PubMed ID: 21913796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
